UFP Technologies Inc

UFP Technologies Inc has a market capitalization of $1.75 billion and trades at a price-to-earnings ratio of 25.61, which is above the industry median of 18.2. The company's price-to-book ratio of 4.13 suggests a premium valuation relative to its book value. The enterprise value to EBITDA ratio of 20.19 indicates a moderate valuation compared to peers in the medical equipment distribution sector. The company's profitability metrics show a return on equity of 16.12% and a return on assets of 10.43%, both of which are above the industry median of 12.5% and 8.7%, respectively. The gross profit margin of 28.3% is in line with the industry median of 27.8%, while the operating margin of 15.3% is slightly below the median of 16.1%. These metrics suggest that UFP Technologies Inc is maintaining strong profitability despite some pressure on operating margins. UFP Technologies Inc's revenue is concentrated in the United States, with 98% of total revenue generated domestically. The company operates in a single business segment focused on medical equipment and supplies distribution. This geographic and segment concentration presents both opportunities and risks, as the company is highly exposed to the U.S. healthcare market. The company's revenue growth has been modest, with a year-over-year increase of 2.1% in the most recent fiscal year. Looking ahead, analysts expect revenue to grow by 4.5% in the next fiscal year. This growth trajectory is in line with the industry median of 3.8% but lags behind the top performers in the sector. UFP Technologies Inc faces moderate liquidity risk, with a current ratio of 2.68 and a debt-to-equity ratio of 0.32. The company has $20.3 million in cash and equivalents but $135.5 million in long-term debt, resulting in a net cash position that is negative after subtracting total debt. The risk assessment indicates a low probability of dilution, with no significant dilution events expected in the near term. Recent investor relations activity shows a mean price target of $324.50, which is 43.5% above the current market price of $226.1. Analysts have issued two "buy" and two "hold" recommendations, with no "strong buy" ratings. This suggests a generally positive outlook but with some caution among analysts.